Table 13.2.

FDA-approved therapeutics under the Emergency Use Authorization (EUA) for combating COVID-19.

S. No.	Date of first EUA issuance	Product	Authorized use
1	May 8, 2020	Propoven 2% (Fresenius Kabi)	Constant infusion of 2% Propoven to maintain sedation in hospitalized suspected or confirmed COVID-19 patients above 16 years of age who need mechanical ventilation in an ICU.
2	May 1, 2020	Remdesivir	Administered only to treat adults and children who are confirmed cases of COVID-19 and in severe patients with SpO2 (blood oxygen saturation level) with or below 94% require external oxygen supplement.

Source: Official Site of US FDA, www.fda.gov.